Expanded testing Recent launches of BKV inSIGHT T-Cell Immunity Panel and ExPeCT anti-CD19 CAR T-cell assay indicate growing demand for specialized immune monitoring; explore partnerships to supply complementary infectious disease and transplant testing services.

CAR T synergy Introduction of CAR T-cell related assays presents cross-sell opportunities with oncology biopharmaceuticals and transplant programs seeking integrated monitoring solutions; position Viracor as a preferred provider for longitudinal CAR T performance data.

New vaccine diagnostics Multiplexed pneumococcal IgG assay including PCV21 expands infectious disease portfolio; target vaccine manufacturers, clinical trial sites, and reference labs needing robust serology panels and high-throughput testing capabilities.

Geographic expansion Facility expansion to Lenexa signals capacity growth; leverage new space to pursue national accounts and hospital systems in the Midwest, offering scalable testing workflows and faster turnaround for critical results.

Upcoming scalability Diverse recent launches and continued lab services emphasis suggest a need for enterprise-grade lab IT and workflow tooling; propose integrated data and reporting solutions leveraging Oracle Cloud, JD Edwards, and Power Apps to streamline operations for partners.